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Abstract
Background: The treatment of microbial infections is becoming increasingly challenging because of limited
therapeutic options and the growing number of pathogenic strains that are resistant to current antibiotics. There is
an urgent need to identify molecules with novel modes of action to facilitate the development of new and more
effective therapeutic agents. The anti-mycobacterial activity of the C17 diyne natural products falcarinol and
panaxydol has been described previously; however, their mode of action remains largely undetermined in
microbes. Gene expression profiling was therefore used to determine the transcriptomic response of Mycobacterium
smegmatis upon treatment with falcarinol and panaxydol to better characterize the mode of action of these C17
diynes.
Results: Our analyses identified 704 and 907 transcripts that were differentially expressed in M. smegmatis after
treatment with falcarinol and panaxydol respectively. Principal component analysis suggested that the C17 diynes
exhibit a mode of action that is distinct to commonly used antimycobacterial drugs. Functional enrichment analysis
and pathway enrichment analysis revealed that cell processes such as ectoine biosynthesis and cyclopropane-fatty-
acyl-phospholipid synthesis were responsive to falcarinol and panaxydol treatment at the transcriptome level in M.
smegmatis. The modes of action of the two C17 diynes were also predicted through Prediction of Activity Spectra
of Substances (PASS). Based upon convergence of these three independent analyses, we hypothesize that the C17
diynes inhibit fatty acid biosynthesis, specifically phospholipid synthesis, in mycobacteria.
Conclusion: Based on transcriptomic responses, it is suggested that the C17 diynes act differently than other anti-
mycobacterial compounds in M. smegmatis, and do so by inhibiting phospholipid biosynthesis.
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Background
Despite significant progress by the World Health
Organization, tuberculosis (TB) remains a global health
emergency with millions of patients succumbing to the
disease annually [1–3]. Although more than 15 TB drug
candidates are currently in pre-clinical or clinical phases
of drug development, new candidates are needed to sup-
plement the drug development pipeline [3, 4]. Highly
bioactive drug candidates can be selected through high-
throughput screening from compound libraries, but it is
difficult to select candidates for further pre-clinical trials
without determining their specific modes of action
(MOAs) [5–9]. It is therefore important to characterize
the MOAs of bioactive molecules early in the drug dis-
covery/development process in order to select candi-
dates with high potential of leading to new and
improved pharmaceuticals [4, 10].
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Metabolic response to environmental stimuli, such as
the introduction of an exogenous chemical, can trigger
specific gene expression responses that are necessary for
growth and survival [11–14]. Transcriptional responses
can therefore provide a global view of an organism’s
response to exogenous chemical stimuli [15–17]. Gene
expression analysis has been used successfully to
characterize the molecular targets of pharmaceuticals
[14, 18, 19]. For example, microarray analysis of
Mycobacterium tuberculosis treated with isoniazid and
rifampin (Fig. 1) not only generated data that was in
good agreement with the known MOAs of these TB
drugs; these studies also improved the knowledge of
indirect and secondary cellular responses of M.
tuberculosis under the effects of those drugs [11, 20, 21].
Microarray data obtained from M. tuberculosis treated
with BTZ043 (Fig. 1), a TB drug candidate in pre-clinical
development, led to the discovery that BTZ043 inhibits
a key enzyme in the synthesis of cell wall arabinans [22].
Thus, transcriptomic profiling can offer a great deal of
insight for drug-organism interactions.
The objective of this study was to determine the tran-
scriptome profile of M. smegmatis following treatment
with falcarinol (1) and panaxydol (2) (Fig. 1) in order to
identify the anti-mycobacterial MOAs of these com-
pounds. Falcarinol and panaxydol were identified as
anti-mycobacterial natural products from studies of the
plant Aralia nudicaulis [23]; however, the anti-
mycobacterial MOA of these two compounds was not
known. Cognisant of the challenges associated with
studying M. tuberculosis in the laboratory, we studied
the closely related, non-pathogenic mycobacteria M.
smegmatis MC2 155 as a surrogate model organism
[24–27]. In addition to fewer safety precautions, other
benefits related to the use of M. smegmatis include
its superior growth rate, its comparable ability to M.
tuberculosis to produce mycolic acid, and the fact that its
genome has been completely sequenced and well anno-
tated, which facilitates transcriptomics analyses [28].
Results and discussion
In order to explore the transcriptomic profile of M.
smegmatis MC2 155 treated with falcarinol and panaxy-
dol, the minimum inhibitory concentrations (MICs) of
the two target compounds and three positive controls,
isoniazid, ethambutol and kanamycin, were measured
using a modified microplate resazurin assay. The MICs
of falcarinol and panaxydol against M. smegmatis MC2
155 were 12.5 and 25 μg/mL respectively (Table 1),
which is higher than their MICs against M. tuberculosis
H37Ra (6.25 and 9.38 μg/mL respectively) [23]. Two of
the positive controls, isoniazid and ethambutol, were se-
lected because information regarding their MOA against
Mycobacterium species is available [29, 30]. Additionally,
M. smegmatis is naturally resistant to isoniazid because
it has different peroxide stress response systems to M.
tuberculosis [31] and the multidrug efflux pump LfrA
[32], although the effect of these resistance mechanisms
has not been investigated at the level of the trans-
criptome. The third positive control, kanamycin, was
Fig. 1 The structures of compounds mentioned in this study
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selected due to its potent activity against M. smegmatis
[32]. The MICs against M. smegmatis that we obtained
for of all three controls were similar to those previously
reported [33, 34].
Microarray analysis revealed that 704 and 907 genes,
or 10 and 13 % of the M. smegmatis transcriptome, were
differentially expressed following treatments with fal-
carinol and panaxydol compared to the control. Using a
fold change threshold of ± 2 and an α value threshold of
p < 0.05, falcarinol and panaxydol treatments resulted in
585 and 788 differentially expressed genes (DEGs)
respectively compared to the vehicle control. When
comparing the two treatments, 99 % of the genes differ-
entially expressed were in common in both treatments,
evidence that the two target compounds act via the same
MOA against M. smegmatis. All gene expression profiles
from the microarray analysis are provided as supplemen-
tary data (Additional file 1).
Principle component analysis (PCA) of all treatments
revealed that exposure of M. smegmatis to 1 and 2 re-
sulted in transcriptomic responses that were more simi-
lar to each other than the controls. Transcript responses
to isoniazid and ethambutol treatments coincided with
the vehicle control while the response to the kanamycin
treatment was the most distinct of all other treatments
(Fig. 2). PCA confirmed that falcarinol and panaxydol
treatments resulted in relatively similar gene responses
suggesting they have a common MOA. Additionally, the
relative distance between the gene responses to 1 and 2
and the three positive controls in PCA provided further
evidence that 1 and 2 have a MOA distinct to those of
the controls; isoniazid and ethambutol both affect cell
wall synthesis and kanamycin primarily targets protein
synthesis (Fig. 2) [35].
Table 1 Anti-mycobacterial activities of falcarinol, panaxydol,








Fig. 2 Principle component analysis of gene expression data. Each point represents one microarray conducted with one biological replicate
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The PCA provided a global view of the differences in
the transcriptomic profiles of treatments; however, it
does not identify what caused these differences. There-
fore, we performed functional enrichment analysis to
examine what biological functions may have contributed
to the differences in transcriptome profiles. All of the
genes in the M. smegmatis MC2 155 genome were
grouped based on their functions by assigning them to
one or multiple gene ontology (GO) terms, which were
grouped into three categories (molecular function, cellu-
lar component and biological processes). In order to
identify the biological functions that were affected by
each treatment, functional enrichment analysis was used
to assess which GO terms in each treatment were sig-
nificantly different to the vehicle control. The GO terms
that were preferentially affected by falcarinol and panax-
ydol treatments were determined from P-values gener-
ated from parametric analysis of gene set enrichment
(PAGE) [36] following a post-hoc analysis with a false
discovery rate (FDR) of 0.01 (Table 2). Nine common
GO terms were found to be significantly different to the
vehicle controls in both treatments, and the processes
that these represent were related to fatty acid biosyn-
thesis, ectoine biosynthesis, and protein metabolism,
transport and biosynthesis. Thus, the C17 diynes appear
to affect multiple pathways within the cell and likely
have different MOAs, however for our discussion we
focus on the prevalent themes based on multiple lines of
evidence from bioinformatics. All functional enrichment
analysis data are included as supplementary data.
To further probe the pathways that were affected by 1
and 2, a pathway enrichment analysis was performed
using the Biocyc online program (http://biocyc.org/)
which uses a Fisher exact test with a post-hoc applica-
tion of the Benjamini-Hochberg method [37]. Differen-
tially affected pathways identified in the falcarinol
treatment included amino acid biosynthesis and fatty
acid biosynthesis, such as “methionine biosynthesis” and
“cyclopropane fatty acids biosynthesis”, whereas fatty
acid biosynthesis was the most prevalent differentially
Table 2 Functional enrichment analysis of gene ontology (GO) terms regulated by falcarinol and panaxydol (P-value < 0.01 after
post-hoc analysis)
Treatment Gene ontology category GO term Name Frequency PAGE Z-Score P-value
Falcarinol Molecular function go:0008658 Penicillin binding 14 5.4 3.0E-05
Molecular function go:0004674 Protein serine/threonine kinase activity 21 5.3 3.6E-05
Molecular function go:0003735 Structural constituent of ribosome 58 5.2 3.9E-05
Biological process go:0045227 Capsule polysaccharide biosynthetic process 7 5.0 6.3E-05
Biological process go:0009088 Threonine biosynthetic process 5 4.9 6.9E-05
Biological process go:0019491 Ectoine biosynthetic process 3 4.9 6.9E-05
Biological process go:0043952 Protein transport by the Sec complex 3 4.9 6.9E-05
Biological process go:0051188 Cofactor biosynthetic process 3 4.9 6.9E-05
Biological process go:0065002 Intracellular protein transmembrane transport 3 4.9 6.9E-05
Biological process go:0006412 Translation 67 4.4 5.0E-04
Cellular component go:0009360 DNA polymerase III complex 6 4.3 8.6E-04
Cellular component go:0005840 Ribosome 46 4.1 1.7E-03
Molecular function go:0003697 Single-stranded DNA binding 7 3.9 5.1E-03
Molecular function go:0019843 rRNA binding 36 3.7 9.5E-03
Molecular function go:0008825 Cyclopropane-fatty-acyl-phospholipid synthase activity 7 2.7 9.6E-03
Panaxydol Molecular function go:0019843 rRNA binding 36 5.7 8.1E-06
Molecular function go:0003735 Structural constituent of ribosome 58 5.5 8.3E-06
Biological process go:0006412 Translation 67 4.7 4.6E-04
Biological process go:0008610 Lipid biosynthetic process 9 4.5 9.3E-04
Cellular component go:0005840 Ribosome 46 4.4 1.1E-03
Molecular function go:0008825 Cyclopropane-fatty-acyl-phospholipid synthase activity 7 4.3 1.3E-03
Biological process go:0019491 Ectoine biosynthetic process 3 4.3 1.3E-03
Biological process go:0043952 Protein transport by the Sec complex 3 4.3 1.3E-03
Biological process go:0065002 Intracellular protein transmembrane transport 3 4.3 1.3E-03
Molecular function go:0004674 Protein serine/threonine kinase activity 21 3.8 9.6E-03
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affected pathway identified in the panaxydol treatment,
such as “pyruvate fermentation to acetate” and “unusual
fatty acid biosynthesis” (Table 3).
Taken together, the results of the functional enrich-
ment and pathway enrichment analysis suggest that
genes coding for ectoine biosynthesis and cyclopropane-
fatty-acyl-phospholipid synthesis are preferentially regu-
lated by the treatment of 1 and 2. Ectoine and its
derivatives are compounds commonly found in bacteria
that balance extracellular osmotic pressure, without al-
tering the ionic strength of the cytoplasm [38, 39]. It has
previously been demonstrated that elevated extracellular
salt concentrations increase ectoine production and
cause up-regulation of the ectoine biosynthetic genes
[40]. Interestingly, falcarinol and panaxydol treatment of
M. smegmatis resulted in the down-regulation of the
ectoine biosynthetic genes ectA, ectB and ectC, suggest-
ing that the C17 diynes do not induce osmotic stress.
Conversely, cyclopropane-fatty-acyl-phospholipid syn-
thesis is the process by which cyclopropane rings are in-
troduced into unsaturated mycolic acids [41, 42]. Indeed,
because this process plays a crucial role in M. tuberculosis
pathogenesis [43], cyclopropane-fatty-acyl-phospholipid
synthase was used as a target for screening potential anti-
TB compounds [44]. Since the two target compounds are
also fatty acid derivatives that share some structural
similarities with precursors of cyclopropane phospholipid
synthesis, we postulate that 1 and 2 act as competitive in-
hibitors of cyclopropane-fatty-acyl-phospholipid synthase
that disrupt mycolic acid metabolism. Inhibition of
mycolic and fatty acid biosynthesis is an acknowledged
mechanism by which compounds can exhibit anti-
mycobacterial activity [45] and inhibitors of these
pathways have been shown to exert their effects on both
M. tuberculosis and M. smegmatis [46]. Natural products
that contain long aliphatic hydrocarbon chains have been
demonstrated to be fatty acid synthesis inhibitors in
Mycobacterium spp. in previous studies. A mixture of two
fatty acids isolated from a Turkish sponge showed signifi-
cant activity (IC50 = 0.35 μg/mL) against the enzyme Fab I,
which is essential for type II fatty acid biosynthesis in M.
tuberculosis [47]. An acetylenic thiolactomycin isolated
from a soil bacterium, Nocardia spp., was found to inhibit
the Fab H fatty acid condensing enzymes, mtFab H and
Kas A, in M. tuberculosis [48]. These two examples sup-
port the hypothesis that the two C17 diynes are fatty acid
Table 3 Pathway enrichment analysis for pathways regulated by falcarinol and panaxydol (P-value < 0.01) after post-hoc analysis and
significantly different genes related to the pathways
Treatment Pathways P-value Genes in Pathway
Falcarinol Threonine biosynthesis 5.3E-05 MSMEG 6286, thrC, thrB, MSMEG 4957, asd, MSMEG6257
Ectoine biosynthesis 6.1E-05 asd, MSMEG 6257, ectC, ectA, ectB
Superpathway of methionine biosynthesis (by
sulfhydrylation)
4.4E-04 MSMEG 4528, metE, metX, MSMEG 1652, MSMEG 4657, asd, MSMEG 6257,
MSMEG 6286
Isoleucine biosynthesis I 4.4E-04 ilvA, ilvH, thrC, thrB, MSMEG 4657, asd, MSMEG 6257, MSMEG 6286




2.1E-03 MSMEG 6386, MSMEG 6399, MSMEG 6382, MSMEG 6401, glf, MSMEG 4947
Homoserine biosynthesis 3.0E-03 MSMEG 4957, asd, MSMEG 6257
Superpathway of methionine biosynthesis
(transsulfuration)
4.7E-03 metE, MSMEG 4957, asd, MSMEG 6257, MSMEG 6286
Unusual Fatty Acid Biosynthesis 5.5E-03 MSMEG 1350, MSMEG 1351, MSMEG 3538
Cyclopropane Fatty Acids Biosynthesis 9.3E-03 MSMEG 1350, MSMEG 1351, MSMEG 3538
Panaxydol Ectoine biosynthesis 3.8E-03 MSMEG 6257, ectC, ectA, ectB
Urea degradation II 3.8E-03 MSMEG 1093, ureC, ureB, ureA
Pyruvate fermentation to acetate VII 5.1E-03 pta, ackA, MSMEG 4646
Pyruvate fermentation to acetate I 5.1E-03 pta
Methionine Biosynthesis 6.3E-03 metE, metN, MSMEG 6257, MSMEG 6286, MSMEG 4528, MSMEG 4527,
metXm MSMEG 1652
Superpathway of methionine biosynthesis (by
sulfhydrylation)
7.7E-03 MSMEG 4528, MSMEG 4527, metE, metX, MSMEG 1652, MSMEG 6257,
MSMEG 6286
Unusual Fatty Acid Biosynthesis 9.7E-03 MSMEG 1205, MSMEG 1350, MSMEG 1351, MSMEG 3538
Cyclopropane Fatty Acids Biosynthesis 9.7E-03 MSMEG 1205, MSMEG 1350, MSMEG 1351, MSMEG 3538
Urate biosynthesis/inosine 5′-phosphate degradation 9.7E-03 MSMEG 1701, MSMEG 4308, guaB, MSMEG 1603
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synthesis inhibitors; however, additional experimental data
are needed to support or refute this hypothesis.
To corroborate the results of our microarray analyses
and confirm that the molecular targets of the two C17
diynes are involved in lipid biosynthesis, we used the
Prediction of the Biological Activity Spectra of Organic
Compounds (PASS) program to explore the prospective
biological activities of 1 and 2 from their chemical struc-
tures. PASS has been used to predict successfully MOAs
of anti-mycobacterial natural products from various
sources [49]. All of the activities that related to lipid bio-
synthesis were contained in the PASS output and the
majority of these were related to phospholipid biosyn-
thesis (Table 4). The complete list of predicted biological
activities of 1 and 2 are presented as supplementary in-
formation. There is therefore excellent congruence be-
tween the predicted activities of the diynes based on
their structure and our transcriptomic data that identi-
fies lipid biosynthesis as the likely pathway affected by
these compounds.
The positive controls, isoniazid, ethambutol and kana-
mycin, with partially or fully known MOAs, were used
as comparison compounds for the C17 diynes. In order
to further validate the hypothesised MOA of 1 and 2
that was generated from microarray data, it is necessary
to discuss the transcriptome profiles of the positive con-
trols in relation to their partially or fully known MOAs.
Isoniazid is thought to inhibit the NADH-dependent
enoyl acyl carrier protein reductase (InhA) in the fatty
acid synthase type II (FAS-II) pathway leading to deple-
tion of mycolic acids in cell wall synthesis [50]. The kas
operon, a set of five FAS-II genes, showed significant
up-regulation in the isoniazid treatment of M. smegmatis
(Additional file 2: Table S1), which is consistent with
previous studies of M. tuberculosis treated with isoniazid
[20, 51, 52]. In addition, similar to isoniazid treated M.
tuberculosis [20], the main target of isoniazid, inhA, did
not show induction in this microarray analysis and the
reason for this observation, both by us and by others, re-
mains unclear. Similar to isoniazid, ethambutol targets
mycobacterial cell wall synthesis. However, instead of
targeting the fatty acid component of cell wall synthesis,
ethambutol inhibits arabinosyl transferases by disrupting
mycobacterial cell wall synthesis [29]. From the pathway
enrichment analysis, ethambutol treatment differentially
affected mycolyl-arabinogalactan-peptidoglycan complex
biosynthesis, heme biosynthesis, and cell structure bio-
synthesis (Additional file 3), whereas a previous prote-
omic analysis of ethambutol treated M. smegmatis also
showed induction of transmembrane alanine and lysine
rich protein in peptidoglycan biosynthesis and several
proteins in the heme biosynthesis pathway [27]. In con-
trast to isoniazid and ethambutol, kanamycin targets the
30S subunit of prokaryotic ribosomes [53]. Interestingly,
many of the genes coding for 30S or 50S ribosomal pro-
teins showed significant down-regulation in this study
(Additional file 2: Table S2). This observation may be ex-
plained by the high dosage of the treatment, which may
have led to the complete inhibition of protein translation
processes. Moreover, the PAGE analysis showed that GO
terms, such as protein targeting, regulation of cell shape,
protein transport by the sec complex, cell wall macro-
molecule biosynthetic processes and intracellular protein
transmembrane transport (Additional file 4), were sig-
nificantly affected by kanamycin treatment. It provided
additional evidence for the cause of cell death by kana-
mycin, which is triggered by mis-translation of the mem-
brane protein [54]. Therefore, there was congruence
between the microarray data and the MOAs of these
well-characterized antibiotics, increasing confidence that
Table 4 Predicted fatty acid synthesis related MOAs of falcarinol and panaxydol using PASS program
Treatment Paa Pib Biological activity
Falcarinol 8.2E-01 8.0E-03 Alkyl-acetyl-glycero-phosphatase inhibitor
8.0E-01 5.0E-03 Fatty-acyl-CoA synthase inhibitor
6.9E-01 1.2E-02 Lipid metabolism regulator
6.2E-01 9.0E-03 Phosphatidyl-glycero-phosphatase inhibitor
4.5E-01 4.3E-02 Alkenyl-glycero-phospho-ethanolamine hydrolase inhibitor
3.6E-01 1.3E-02 Cyclopropane-fatty-acyl-phospholipid synthase inhibitor
Panaxydol 6.7E-01 2.4E-02 Alkyl-acetyl-glycero-phosphatase inhibitor
6.7E-01 1.6E-02 Fatty-acyl-CoA synthase inhibitor
6.6E-01 1.4E-02 Lipid metabolism regulator
3.4E-01 3.6E-02 Phosphatidyl-glycero-phosphatase inhibitor
3.8E-01 6.5E-02 Alkenyl-glycero-phospho-ethanolamine hydrolase inhibitor
2.7E-01 3.7E-02 Cyclopropane-fatty-acyl-phospholipid synthase inhibitor
a Probability to be active
b Probability to be inactive
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Fig. 3 (See legend on next page.)
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the microarray analyses of 1 and 2 provide insight into
their MOA.
Microarray data were further verified by real-time
polymerase chain reaction (PCR). Expression data were
analyzed using the Kruskal-Wallis test with Dunn’s
method for joint ranking. MSMEG 3359, MSMEG 3805
and 4-carboxymuconolactone decarboxylase (pcaC)
showed expression patterns across each group that were
consistent with the microarray data (Fig. 3). The real-
time PCR and microarray data were significantly
correlated in a linear regression model (Additional file 2:
Figure S1). The gene pcaC is involved in the catabolism
of protocatechuate to succinate and acetyl-CoA in the
beta-ketoadipate pathway [55]. The increased expression
of pcaC by the treatment of INH, which confers natural
resistance of M. smegmatis against INH, may be a com-
pensatory response to increase production of acetyl-CoA
[56]. The mRNA levels of both MSMEG 3359 and
MSMEG 3805 were higher in the panaxydol treatments
compared to the negative control and isoniazid, sug-
gesting that these genes are involved in the response
to these compounds, however, functional data for
MSMEG 3359 and MSMEG 3805 are lacking in the
literature. The amplicons of the genes used in real-
time PCR are provided in the supplementary data
(Additional file 2: Table S3).
Conclusion
Using microarray analysis and PASS, we hypothesize that
both falcarinol and panaxydol inhibit phospholipid bio-
synthesis in mycobacteria and suggest that further stud-
ies should be directed at supporting or refuting this
hypothesized MOA. To test this hypothesis, the en-
zyme(s) that 1 and 2 act upon should be isolated and an
enzyme inhibition assay performed to measure the bind-
ing affinity of falcarinol and panaxydol to the enzyme.
Cognisant that there are likely additional mechanisms of
action for the C17 diynes within the cell that may not be
reflected in a transcriptomic response, further studies
should also include additional methods to elucidate the
full effect of these compounds.
Methods
Mycobacterium smegmatis growth condition and
treatments
Mycobacterium smegmatis strain MC2 155 (American
Type Culture Collection [ATCC] 700084) was grown in
Middlebrook 7H9 (Becton Dickinson, Mississauga, Ontario
[ON], Canada) broth supplemented with 10 % albumin
dextrose catalase (ADC) enrichment (Becton Dickinson,
Mississauga, ON, Canada) and 0.2 % glycerol at 37 °C for
72 h in a humid environment before being diluted to a tur-
bidity equivalent to a 1.0 McFarland standard (107 colony
forming units [CFU]) using the same modified 7H9 broth
and cryogenically preserved (−80 °C; 1.5 mL aliquots).
Cryopreserved M. smegmatis was thawed and diluted
with modified Middlebrook 7H9 broth (1:5) resulting
in the mycobacterial suspension (2 × 106 CFU) used
for the bioassays.
The MIC of target treatments (1 and 2) and positive
controls (isoniazid, ethambutol and kanamycin) were
measured using a M. smegmatis bioassay, which was
modified from a microplate resazurin assay previously
developed in our laboratory [57] by changing the resa-
zurin addition time and total incubation time from 72
and 96 h to 24 and 48 h, respectively.
To prepare cultures of M. smegmatis for gene expres-
sion analysis, cyropreserved M. smegmatis suspensions
were diluted as described above and transferred to 96 well
plates. The plates were first incubated for 48 h to reach
log phase growth and then each treatment, including one
vehicle control, three positive controls and two target
compounds, was added to corresponding rows of a 96 well
plate except the peripheral wells resulting in 10 wells per
treatment. The vehicle control consisted of modified 7H9
broth with 2 % dimethyl sulfoxide (DMSO), whereas the
concentrations of positive controls and target compounds
were 10 ×MIC for each treatment against M. smegmatis.
The plates were incubated at 37 °C for 6 h in a humid en-
vironment. The bioassay time point and doses were
chosen based on previously published studies [11, 20, 21].
Following 6 h incubation, wells containing the same treat-
ment in each plate were pooled into a 1.5 mL centrifuge
tube and bacteria were harvested by centrifugation. The
vehicle control and two positive controls (isoniazid and
ethambutol) each had six biological replicates; the two tar-
get treatments (falcarinol and panaxydol) and one add-
itional positive control (kanamycin) each had seven
biological replicates. All biological replicates were used for
microarray analysis and real-time PCR.
RNA extraction
Total ribonucleic acid (RNA) was extracted using TRI-
zol® (Invitrogen, Burlington, ON, Canada) and purified
(See figure on previous page.)
Fig. 3 Real time PCR comparison to expression data from the microarray (log2) for (A) pcaC (B) MSMEG 3359 and (C) MSMEG 3805. The horizontal
line in the box plots represents the median of the group, the boundaries of the box represent the 10th and 90th percentiles and the minimum
and maximum data points are represented by the whiskers (Prism v5.0). Differences among groups were tested using a Kruskal Wallis test with
Dunn method for joint ranking. The small case letters “a”, “b” and “c” were used to represent different groups. NT = negative treatment, INH = isoniazid,
Pa = panaxydol, Fa = falcarinol, Ka = kanamycin, EMB = ethambutol
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using an RNeasy® kit (Qiagen, Toronto, ON, Canada) ac-
cording to the manufacture’s protocol. RNA quantity
was measured on a NanoDrop ND 2000 spectrometer
(Thermo Scientific, Wilmington, DE, USA) before and
after purification. RNA quality was evaluated using an
Agilent 2100 Bioanalyzer (Agilent, Mississauga, ON,
Canada). All samples used in the microarray and real-
time PCR experiments had RNA integrity numbers
(RINs) > 7.5.
Microarray analysis and bioinformatics
Mycobacterium smegmatis 8 × 15 K Agilent microarrays
(designed by Genotypic Technology, Bengaluru, India
and manufactured by Agilent, Santa Clara, CA, USA)
was used to investigate global mRNA profiles of M.
smegmatis treated with 1 and 2. RNA labeling,
microarray hybridization, and microarray scanning were
conducted as directed in the Agilent one-colour
microarray-based gene expression analysis protocol. Raw
expression data along with tif images were extracted
using Agilent Feature Extraction Software (v10.7.3.1). All
microarray data reported in this study follow established
guidelines (i.e. Minimum Information about a Micro-
array Experiment http://www.ncbi.nlm.nih.gov/geo/info/
MIAME.html) and have been deposited in the National
Center for Biotechnology Information (NCBI) Gene Ex-
pression Omnibus (GEO) database (GSE64323, GPL19567).
The raw expression data were normalized using Loess
normalization (smoothing factor of 0.2). The limit of de-
tection of the microarray normalized signals was deter-
mined to be 3.5 based on the lower limit of the standard
curve for Agilent quality controls and negative controls
(dark corners) so all intensity values that were lower
than 3.5 were assigned a value of 3.5. DEGs were deter-
mined using one-way analysis of variance (ANOVA)
followed by a post-hoc test using Benjamini and Hoch-
berg method with a FDR at 0.01. PCA was performed on
all transcripts using normalized expression values. Func-
tional enrichment of GO terms was performed using
PAGE analysis [36] followed by a post-hoc test using
Benjamini and Hochberg method with FDR set at 0.01.
The above data processing and bioinformatics analysis
were performed in JMP® Genomics (v5.1).
DEGs (adjusted P-value < 0.01) obtained from ANOVA
was uploaded to Biocyc online program (http://biocyc.org/)
[58], and pathway enrichment analysis was performed using
Fisher’s extract test with Benjamini-Hochberg [59] method
as a post-hoc analysis.
cDNA synthesis, primer design and real-time PCR
The complementary deoxyribose nucleic acid (cDNA)
synthesis, primer design and real-time PCR were per-
formed as previously reported [60]. Primers used in this
study are listed in Table 5. Mean expression levels of
MSMEG 3584, MSMEG 5570 and gidB were determined
to be the most stable combination of control genes to
normalize all target expression data, with a mean M-
value of 0.67 (mean coefficient variance = 0.25) as deter-
mined by the target stability function in CFX96 software.
Normalized gene expression values were extracted using
a relative ΔΔCq method in CFX Manager™ 3.0 software
(BioRad, Mississauga, ON, Canada). Normalized expres-
sion data were not normally distributed and a Kruskal–
Wallis non-parametric test was used to determine if
gene expression levels varied across treatments and a
non-parametric Dunn method for joint ranking was used
as a post-hoc test to determine which treatments were
different from each other. All statistical analyses were
conducted in GraphPad Prism 5.0.
Table 5 Primer sequences used for real-time PCR with amplicon size and annealing temperature. All primer sets had R2 > 0.98 and
efficiency percentage between 90 % and 110 %
Gene Forward primer (5′-3′) Reverse primer (5′-3′) Product size (bp) Annealing (°C)
alkB (MEMEG 1839) GCCTACATCCCGTTCCAGT AGCGAGTCCTTCTTGTGTCC 191 58
ectB (MSMEG 3900) AGGATTTTTCCGTGTTGCTC TTGTTGTGCCCGTAGTTCAG 214 58
katG (MSMEG 3461) GCCACCCAGGAAGAGACC GCAGGTTGACGAAGAAGTCC 265 58
mmpl5 (MSMEG 1382) CGAATCTGGCTACCTGTGCT GTGGCGGTCCTCTCTTCTTT 365 58
MSMEG 3359 CACCGACATACACTGCCAAC GAACCACGCCTTCTCCTG 310 58
MSMEG 3805 GGGGAGCCATTCTCAACG TGTGTTCCTCGGGCAGTTC 225 59
pcaC (MSMEG 6370) CGAGACCGAGCAGCGACT CGGGAACGGCATCTTCAC 250 59
gidB (MSMEG 6940)1 ATGCCAGGGTGGTGAGAT CGTGAAACATTCGGCTTCT 270 61
MSMEG 3496 TATGAGCGTGGTGGTCCTG GCGGTCGTTGTAGTTGGTCT 229 61
MSMEG 3584a TGTCGGAGTTGTTGATGGTC CTGTCGGTGTTCTCGTTCAG 241 61
MSMEG 5570a CACCGAGAAAGAACTGAGCA GCAACTATTCCCACACAACCT 173 60
a Genes used as normalizer gene
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Prediction of biological activities
The structures of 1 and 2 were converted to simplified
molecular-input line-entry system (SMILES) format and
uploaded to Prediction of the biological activity spectra
of organic compounds (PASS) online program (http://
www.way2drug.com/PASSOnline) for biological activity
prediction [61]. A master list, which entails all potential
bioactivities of the two target compounds and probabilities
of each bioactivity being active or inactive, was generated
through the PASS online program (Additional file 5) [61].
Additional files
Additional file 1: ANOVA results for all transcripts in each treatment
group compared to vehicle control. (XLSX 24787 kb)
Additional file 2: Supplementary data; Figure S1. Correlation of fold
change (log10) between real-time PCR and microarray data; Table S1.
Sequenced genes and their amplicons in M. smegmatis; Table S2.
Response of the kas operon in M. smegmatis to isoniazid treatment
compared with vehicle control; Table S3. Fold changes of significantly
different ribosomal protein genes from M. smegmatis treated with
kanamycin. (DOCX 91 kb)
Additional file 3: Enriched pathways for each treatment group. (XLSX 32 kb)
Additional file 4: Enriched GO terms for each treatment group.
(XLSX 231 kb)
Additional file 5: Predicted bioactivities for falcarinol and panaxydol
from PASS. (XLSX 81 kb)
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